Protembis Financing Will Support ProtEmbo Cerebral Protection System’s Pivotal Trial

March 26, 2024—Protembis GmbH, a privately-held emerging cardiovascular medical device company based in Aachen, Germany, announced the completion of a €30 million Series B financing round to support the enrollment of the PROTEMBO investigational device exemption (IDE) pivotal trial of the ProtEmbo cerebral protection system.

Additionally, the company announced the addition of Keith D. Dawkins, MD, to its Board of Directors. Dr. Dawkins has been the Chief Medical Officer (CMO) of Shockwave since 2019. Before that, he was Global CMO and held senior positions at Boston Scientific since 2008. For more than 20 years, he was a practicing interventional cardiologist in the United Kingdom, where he served as President of the British Cardiovascular Intervention Society and authored more than 750 academic publications and presentations.

According to the company, ProtEmbo is an intra-aortic filter device designed to protect the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). The low-profile nonthrombogenic system is intended to shield all cerebral vessels. It is delivered through the left radial artery for optimal placement and stability. This access site allows physicians to avoid interference with TAVR equipment typically delivered through the femoral artery, noted the Protembis.

The funding round was structured in two separate capital increases which have both been completed. It was led by a European consortium of venture capital investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture, and Germany-based TechVision Fund. Other investors include Coparion, several large family offices, angel investors, and a multinational medical device strategic, advised the company.